Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Creo Medical ( (GB:CREO) ) has shared an update.
Creo Medical’s SpydrBlade Flex device has been successfully used in two Bariatric Endoscopic Antral Myotomy procedures by Professor Christopher C. Thompson, a leading figure in bariatric endoscopy and originator of the BEAM technique. The early clinical use, presented at the Frontiers in Endoscopic Surgery 2026 forum, showcased SpydrBlade Flex’s ability to perform precise full-thickness antral myotomy, underscoring its suitability for complex third-space and bariatric endoscopic interventions.
Powered by Creo’s CROMA advanced energy platform, SpydrBlade Flex is positioned to support the growing field of minimally invasive metabolic and bariatric endoscopy, which sits between drug-based therapies and surgery. The company says this validation by a key opinion leader reinforces SpydrBlade Flex as a core element of its advanced GI portfolio and aligns with its strategy to drive platform utilisation by expanding clinical applications and collaborations with leading centres of excellence.
Spark’s Take on CREO Stock
According to Spark, TipRanks’ AI Analyst, CREO is a Neutral.
The score is held back primarily by poor financial performance (sharp revenue decline, large losses, and continued cash burn). Technicals are a partial offset with strong trend and positive MACD, but very overbought RSI increases near-term risk. Valuation impact is neutral since P/E and dividend yield were not provided.
To see Spark’s full report on CREO stock, click here.
More about Creo Medical
Creo Medical Group is a UK-based medical device company focused on minimally invasive electrosurgical technologies for therapeutic endoscopy. Its portfolio is built around the CROMA advanced energy platform, which combines bipolar radiofrequency and microwave energy to power a suite of patented devices aimed at improving precision, safety and cost-efficiency in gastrointestinal and other endoscopic procedures.
Average Trading Volume: 707,873
Technical Sentiment Signal: Sell
Current Market Cap: £52.07M
For an in-depth examination of CREO stock, go to TipRanks’ Overview page.